Editas Medicine Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Advance New CRISPR/Cas9 Medicines
-Editas to Receive up to $5 Million Award to Fund Genome Editing Research-
"We are delighted to work with Cystic Fibrosis Foundation Therapeutics to discover and develop medicines for people with cystic fibrosis," said
"We believe that the CRISPR approach to gene editing holds significant promise for repairing the underlying cause of cystic fibrosis," said
The gene that causes CF encodes the cystic fibrosis transmembrane conductance regulator protein (CFTR), which helps maintain the water balance within the lung and in other tissues. Mutations in this gene lead to problems with the flow of fluids and salt into and out of cells. This causes a thick buildup of mucus in the lungs, pancreas and other organs. The mucus clogs the airways and traps bacteria, leading to chronic infections and inflammation of the airways. There are more than 1,800 known mutations within the CFTR gene. As part of this agreement,
About
Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company's product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption "Risk Factors" included in the Company's Annual Report on Form 10-K, which is on file with the
Media Contact
Dan Budwick
Pure Communications, Inc.
(973) 271-6085
dan@purecommunicationsinc.com
Investor ContactJesse Baumgartner
Stern Investor Relations, Inc
(212) 362-1200jesse@sternir.com